# Nodes-and-connections RNAi knockdown screening: identification of a signaling molecule network involved in fulvestrant action and breast cancer prognosis

**Authors:** N Miyoshi, B S Wittner, K Shioda, T Hitora, T Ito, S Ramaswamy, K J Isselbacher, D C Sgroi, T Shioda

PMC · DOI: 10.1038/oncsis.2015.32 · 2015-10-19

## TL;DR

A new RNAi screening method identifies a network of signaling molecules involved in breast cancer treatment and prognosis.

## Contribution

The nodes-and-connections RNAi screening approach systematically maps target interactions to reveal signaling networks relevant to drug action and prognosis.

## Key findings

- A 19-node interaction map was generated, involving death-associated protein kinases (DAPKs) and related signaling molecules.
- Five experimentally validated nodes and three predicted nodes showed significant prognostic value in breast cancer.
- Synchronized expression of 10 nodal proteins in breast cancer tissues supports their functional interactions.

## Abstract

Although RNA interference (RNAi) knockdown screening of cancer cell cultures is an effective approach to predict drug targets or therapeutic/prognostic biomarkers, interactions among identified targets often remain obscure. Here, we introduce the nodes-and-connections RNAi knockdown screening that generates a map of target interactions through systematic iterations of in silico prediction of targets and their experimental validation. An initial RNAi knockdown screening of MCF-7 human breast cancer cells targeting 6560 proteins identified four signaling molecules required for their fulvestrant-induced apoptosis. Signaling molecules physically or functionally interacting with these four primary node targets were computationally predicted and experimentally validated, resulting in identification of four second-generation nodes. Three rounds of further iterations of the prediction–validation cycle generated third, fourth and fifth generation of nodes, completing a 19-node interaction map that contained three predicted nodes but without experimental validation because of technical limitations. The interaction map involved all three members of the death-associated protein kinases (DAPKs) as well as their upstream and downstream signaling molecules (calmodulins and myosin light chain kinases), suggesting that DAPKs play critical roles in the cytocidal action of fulvestrant. The in silico Kaplan–Meier analysis of previously reported human breast cancer cohorts demonstrated significant prognostic predictive power for five of the experimentally validated nodes and for three of the prediction-only nodes. Immunohistochemical studies on the expression of 10 nodal proteins in human breast cancer tissues not only supported their prognostic prediction power but also provided statistically significant evidence of their synchronized expression, implying functional interactions among these nodal proteins. Thus, the Nodes-and-Connections approach to RNAi knockdown screening yields biologically meaningful outcomes by taking advantage of the existing knowledge of the physical and functional interactions between the predicted target genes. The resulting interaction maps provide useful information on signaling pathways cooperatively involved in clinically important features of the malignant cells, such as drug resistance.

## Linked entities

- **Chemicals:** fulvestrant (PubChem CID 104741)
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** MAP2K2 (mitogen-activated protein kinase kinase 2) [NCBI Gene 5605] {aka CFC4, MAPKK2, MEK2, MKK2, PRKMK2}, CSNK1E (casein kinase 1 epsilon) [NCBI Gene 1454] {aka CKIe, CKIepsilon, HCKIE}, MPP7 (MAGUK p55 scaffold protein 7) [NCBI Gene 143098], MYL9 (myosin light chain 9) [NCBI Gene 10398] {aka LC20, MLC-2C, MLC2, MMIHS4, MRLC1, MYRL2}, PRKAB2 (protein kinase AMP-activated non-catalytic subunit beta 2) [NCBI Gene 5565], DGKB (diacylglycerol kinase beta) [NCBI Gene 1607] {aka DAGK2, DGK, DGK-BETA}, PAWR (pro-apoptotic WT1 regulator) [NCBI Gene 5074] {aka PAR4, Par-4}, MAPK9 (mitogen-activated protein kinase 9) [NCBI Gene 5601] {aka JNK-55, JNK2, JNK2A, JNK2ALPHA, JNK2B, JNK2BETA}, MAPK11 (mitogen-activated protein kinase 11) [NCBI Gene 5600] {aka P38B, P38BETA2, PRKM11, SAPK2, SAPK2B, p38-2}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, PHKG2 (phosphorylase kinase catalytic subunit gamma 2) [NCBI Gene 5261] {aka GSD9C}, KSR1 (kinase suppressor of ras 1) [NCBI Gene 8844] {aka KSR, RSU2}, ULK1 (unc-51 like autophagy activating kinase 1) [NCBI Gene 8408] {aka ATG1, ATG1A, UNC51, Unc51.1, hATG1}, GRK1 (G protein-coupled receptor kinase 1) [NCBI Gene 6011] {aka GPRK1, RHOK, RK}, DAPK3 (death associated protein kinase 3) [NCBI Gene 1613] {aka DLK, ZIP, ZIPK}, CDK10 (cyclin dependent kinase 10) [NCBI Gene 8558] {aka ALSAS, PISSLRE}, CSK (C-terminal Src kinase) [NCBI Gene 1445], NEK10 (NIMA related kinase 10) [NCBI Gene 152110] {aka CILD44}, DAXX (death domain associated protein) [NCBI Gene 1616] {aka BING2, DAP6, EAP1}, CAMK1D (calcium/calmodulin dependent protein kinase ID) [NCBI Gene 57118] {aka CKLiK, CaM-K1, CaMKID}, EPHA2 (EPH receptor A2) [NCBI Gene 1969] {aka ARCC2, CTPA, CTPP1, CTRCT6, ECK}, NR3C1 (nuclear receptor subfamily 3 group C member 1) [NCBI Gene 2908] {aka GCCR, GCR, GCRST, GR, GRL}, MAPK6 (mitogen-activated protein kinase 6) [NCBI Gene 5597] {aka ERK3, HsT17250, PRKM6, p97MAPK}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, CKMT2 (creatine kinase, mitochondrial 2) [NCBI Gene 1160] {aka SMTCK}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, RPS6KB2 (ribosomal protein S6 kinase B2) [NCBI Gene 6199] {aka KLS, P70-beta, P70-beta-1, P70-beta-2, S6K-beta2, S6K2}, PRKAG3 (protein kinase AMP-activated non-catalytic subunit gamma 3) [NCBI Gene 53632] {aka AMPKG3, SMGMQTL}, MYLK3 (myosin light chain kinase 3) [NCBI Gene 91807] {aka MLCK, MLCK2, caMLCK}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, DAPK1 (death associated protein kinase 1) [NCBI Gene 1612] {aka DAPK, ROCO3}, ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase) [NCBI Gene 6098] {aka MCF3, ROS, c-ros-1}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, MYH14 (myosin heavy chain 14) [NCBI Gene 79784] {aka DFNA4, DFNA4A, FP17425, MHC16, MYH17, NMHC II-C}, PDGFRL (platelet derived growth factor receptor like) [NCBI Gene 5157] {aka PDGRL, PRLTS}, ACVRL1 (activin A receptor like type 1) [NCBI Gene 94] {aka ACVRLK1, ALK-1, ALK1, HHT, HHT2, ORW2}, CHKB (choline kinase beta) [NCBI Gene 1120] {aka CHETK, CHKL, CK, CKB, CKEKB, EK}, CAMK4 (calcium/calmodulin dependent protein kinase IV) [NCBI Gene 814] {aka CaMK IV, CaMK-GR, CaMKIV, caMK}, STAT5B (signal transducer and activator of transcription 5B) [NCBI Gene 6777] {aka GHISID2, STAT5}, FLT4 (fms related receptor tyrosine kinase 4) [NCBI Gene 2324] {aka CHTD7, FLT-4, FLT41, LMPH1A, LMPHM1, PCL}, ACVR1B (activin A receptor type 1B) [NCBI Gene 91] {aka ACTRIB, ACVRLK4, ALK4, SKR2}, CALM1 (calmodulin 1) [NCBI Gene 801] {aka CALML2, CAM2, CAM3, CAMB, CAMC, CAMI}, ATF4 (activating transcription factor 4) [NCBI Gene 468] {aka CREB-2, CREB2, TAXREB67, TXREB}, TESK1 (testis associated actin remodelling kinase 1) [NCBI Gene 7016], PTK7 (protein tyrosine kinase 7 (inactive)) [NCBI Gene 5754] {aka CCK-4, CCK4}, CDK15 (cyclin dependent kinase 15) [NCBI Gene 65061] {aka ALS2CR7, PFTAIRE2, PFTK2}, PRKAR1A (protein kinase cAMP-dependent type I regulatory subunit alpha) [NCBI Gene 5573] {aka ACRDYS1, ADOHR, CAR, CNC, CNC1, PKR1}, GRK3 (G protein-coupled receptor kinase 3) [NCBI Gene 157] {aka ADRBK2, BARK2}, BIK (BCL2 interacting killer) [NCBI Gene 638] {aka BIP1, BP4, NBK}, ERBB4 (erb-b2 receptor tyrosine kinase 4) [NCBI Gene 2066] {aka ALS19, HER4, p180erbB4}, F2RL3 (F2R like thrombin or trypsin receptor 3) [NCBI Gene 9002] {aka PAR4}, NME5 (NME/NM23 family member 5) [NCBI Gene 8382] {aka CILD48, NDK5, NM23-H5, NM23H5, RSPH23}, FASTKD3 (FAST kinase domains 3) [NCBI Gene 79072], MYLK (myosin light chain kinase) [NCBI Gene 4638] {aka AAT7, KRP, MLCK, MLCK1, MLCK108, MLCK210}, NODAL (nodal growth differentiation factor) [NCBI Gene 4838] {aka HTX5}, PKMYT1 (protein kinase, membrane associated tyrosine/threonine 1) [NCBI Gene 9088] {aka MYT1, PPP1R126}, PLK1 (polo like kinase 1) [NCBI Gene 5347] {aka PLK, STPK13}, PRKCZ (protein kinase C zeta) [NCBI Gene 5590] {aka PKC-ZETA, PKC2}, MYL2 (myosin light chain 2) [NCBI Gene 4633] {aka CMH10, MFM12, MLC-2, MLC-2s/v, MLC-2v, MLC2}
- **Diseases:** metastasis (MESH:D009362), infected (MESH:D007239), toxicity (MESH:D064420), breast cancer (MESH:D001943), Cancer (MESH:D009369), node/ (MESH:D012804)
- **Chemicals:** Fulvestrant (MESH:D000077267), paraffin (MESH:D010232), polybrene (MESH:D006583), CO2 (MESH:D002245), puromycin (MESH:D011691), formalin (MESH:D005557), Ca2+ (-), hydrogen peroxide (MESH:D006861), crystal violet (MESH:D005840), 17beta-estradiol (MESH:D004958), tamoxifen (MESH:D013629)
- **Species:** Vesicular stomatitis virus (species) [taxon 11276], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** W2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z791), HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), pMD2G — Homo sapiens (Human), Hybridoma (CVCL_A6KF), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), dR8.91 — Rattus norvegicus (Rat), Carcinoma of the rat kidney, Cancer cell line (CVCL_WX08)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC4632093/full.md

---
Source: https://tomesphere.com/paper/PMC4632093